4.8 Article

The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 133, Issue 18, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI169608

Keywords

-

Ask authors/readers for more resources

Protease-activated receptor 4 (PAR4) gene harbors a functional dimorphism associated with greater platelet aggregation, and the A allele frequency is more common in Black individuals. In this study, it was found that the A allele is associated with worse stroke outcomes and increased risk of incident ischemic stroke. Mice studies further demonstrated that mice expressing the Thr120 variant had worse stroke outcomes mediated by enhanced platelet activation and platelet-neutrophil interactions, while specific antiplatelet therapy showed improvement only in mice expressing the Ala120 variant.
Protease-activated receptor 4 (PAR4) (gene F2RL3) harbors a functional dimorphism, rs773902 A/G (encoding Thr120/Ala120, respectively) and is associated with greater platelet aggregation. The A allele frequency is more common in Black individuals, and Black individuals have a higher incidence of ischemic stroke than White individuals. However, it is not known whether the A allele is responsible for worse stroke outcomes. To directly test the in vivo effect of this variant on stroke, we generated mice in which F2rl3 was replaced by F2RL3, thereby expressing human PAR4 (hPAR4) with either Thr120 or Ala120. Compared with hPAR4 Ala120 mice, hPAR4 Thr120 mice had worse stroke outcomes, mediated in part by enhanced platelet activation and platelet-neutrophil interactions. Analyses of 7,620 Black subjects with 487 incident ischemic strokes demonstrated the AA genotype was a risk for incident ischemic stroke and worse functional outcomes. In humanized mice, ticagrelor with or without aspirin improved stroke outcomes in hPAR4 Ala120 mice, but not in hPAR4 Thr120 mice. P selectin blockade improved stroke outcomes and reduced platelet-neutrophil interactions in hPAR4 Thr120 mice. Our results may explain some of the racial disparity in stroke and support the need for studies of nonstandard antiplatelet therapies for patients expressing PAR4 Thr120.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available